These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 34218424)

  • 1. The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.
    Wang L; Zhou MB; Zhang H
    Ophthalmol Ther; 2021 Sep; 10(3):465-494. PubMed ID: 34218424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases.
    Navarro-Partida J; Castro-Castaneda CR; Santa Cruz-Pavlovich FJ; Aceves-Franco LA; Guy TO; Santos A
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advance of nanoparticle-based topical drug delivery to the posterior segment of the eye.
    Wang Y; Xu X; Gu Y; Cheng Y; Cao F
    Expert Opin Drug Deliv; 2018 Jul; 15(7):687-701. PubMed ID: 29985660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular drug delivery systems: An overview.
    Patel A; Cholkar K; Agrahari V; Mitra AK
    World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina.
    Wang L; Zhang H
    Drug Deliv Transl Res; 2023 Feb; 13(2):547-567. PubMed ID: 36129668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.
    Schopf LR; Popov AM; Enlow EM; Bourassa JL; Ong WZ; Nowak P; Chen H
    Transl Vis Sci Technol; 2015 Jun; 4(3):11. PubMed ID: 26101724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Topical Ocular Drug Delivery.
    Yellepeddi VK; Palakurthi S
    J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology-based formulations to amplify intraocular bioavailability.
    Kagkelaris K; Panayiotakopoulos G; Georgakopoulos CD
    Ther Adv Ophthalmol; 2022; 14():25158414221112356. PubMed ID: 35873277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation.
    Mazet R; Yaméogo JBG; Wouessidjewe D; Choisnard L; Gèze A
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32575411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations.
    Loftsson T; Sigurdsson HH; Konrádsdóttir F; Gísladóttir S; Jansook P; Stefánsson E
    Pharmazie; 2008 Mar; 63(3):171-9. PubMed ID: 18444504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
    Bisht R; Mandal A; Jaiswal JK; Rupenthal ID
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28425224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming the Anatomical and Physiological Barriers in Topical Eye Surface Medication Using a Peptide-Decorated Polymeric Micelle.
    Lin S; Ge C; Wang D; Xie Q; Wu B; Wang J; Nan K; Zheng Q; Chen W
    ACS Appl Mater Interfaces; 2019 Oct; 11(43):39603-39612. PubMed ID: 31580053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review on contact lens for ophthalmic drug delivery.
    Xu J; Xue Y; Hu G; Lin T; Gou J; Yin T; He H; Zhang Y; Tang X
    J Control Release; 2018 Jul; 281():97-118. PubMed ID: 29782944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration.
    Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD
    Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).
    Cholkar K; Gilger BC; Mitra AK
    Int J Pharm; 2016 Feb; 498(1-2):326-34. PubMed ID: 26706439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
    Srinivasarao DA; Lohiya G; Katti DS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prominence of the dosage form design to treat ocular diseases.
    Campos PM; Petrilli R; Lopez RFV
    Int J Pharm; 2020 Aug; 586():119577. PubMed ID: 32622806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocrystal for ocular drug delivery: hope or hype.
    Sharma OP; Patel V; Mehta T
    Drug Deliv Transl Res; 2016 Aug; 6(4):399-413. PubMed ID: 27165145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.